Yony Lamdan's Contact Details

Yony Lamdan's Company Details

Yemoja Ltd.

תל-חי, North District, Israel • 16 Employees
Research

Yemoja is mastering cultivated pure microalgae – bringing the compelling value of Earth's original super crop to the world. Yemoja's pioneering cultivation methods, distinct microalgae cultivation expertise and world-class production facilities give companies access to high-value microalgae of any variety at any desired scale. With its industry-leading knowhow and platform, Yemoja can fast-track both existing microscopic algae products and solutions under development. Yemoja optimizes microalgae purity, quality and yield with proven reproducibility, hurdling previous industry limitations. Only a tiny fraction of the oceans' estimated 200,000 to 800,000 microalgae species have been discovered, and only about a dozen have been commercialized thus far. Yemoja explores, develops and grows microalgae products, to introduce clients to this largely untapped market. The potential is vast for natural, vegan, bioactive microalgae's applications in food and nutraceuticals, as well as in cosmetics, cosmeceuticals and pharmaceutical formulations. Yemoja's state-of-the-art indoor cultivation facility is the gold standard in climate management and sustainability. The company has launched industry 4.0 for microalgae cultivation – with precision biology, high-caliber automation and sophisticated engineering methods. The patented hyper-controlled, closed cultivation method uses high-precision, rapid photobioreactor technology. This next-gen platform manages a broad array of parameters in micro or macro units in a contamination-proof system, supporting endless customization options. Yemoja leverages a prodigious range microalgae species with an abundance of nutritional benefits, including pharmaceutical grade varieties, which can be tailored to a full spectrum of applications.Yemoja was founded in 2017 by a team of seasoned marine biology and biotech experts with extensive experience in the microalgae and biopharmaceutical industries.